Logo

Strategic Sale of $7B Business Unit – Pharma & Biotech

Facilitated Day 1 readiness, TSA management, and organizational design to support a seamless strategic sale and stable post-separation transition across 80+ countries.

Industry

Pharma & Biotech

Client

Large Enterprise

Engagement Duration

12–24 months

Location

Kenilworth, NJ

Strategic Sale of $7B Business Unit – Pharma & Biotech-banner

The Challenge

A large enterprise needed to divest its $7B Rx business unit through a strategic sale. This complex transaction involved coordinating Day 1 readiness across more than 80 countries, managing TSAs, and designing a future-state organizational model — all while ensuring business continuity and cost efficiency.

Our Approach

  • Designed and executed a comprehensive Day 1 readiness plan for global operations.
  • Developed standalone costing models and operating plans to prepare for the transition.
  • Established TSA structures and timelines to support a smooth separation.
  • Designed organizational structures for post-divestiture operations.

In-depth Details

  • Coordinated cross-functional global teams across 80+ markets to achieve readiness milestones.
  • Developed governance frameworks to monitor TSA execution and mitigate operational risk.
  • Implemented change management and communication strategies to prepare stakeholders for transition.

$7B

Transaction Value

80+

global markets

12–24

months Engagement Duration

of a complex global ERP platform

Result

Successfully facilitated the strategic sale. Delivered a stable, efficient post-separation transition. Maintained operational continuity while meeting all Day 1 readiness requirements.

quote

Strategy MA was a game-changer for us. Their expertise in M&A and tech strategy helped us navigate a complex integration. They didn’t just advise, they became an extension of our team and delivered results beyond expectations. Highly recommend them for real impact

Jack Wilnor

CEO